Tumour kinetics in multiple myeloma before, during, and after treatment

Leukemia and Lymphoma

Volumn 40, Issue 3-4, 2001, Pages 373-384

  Lincz, L F ^a   Crooks, R L ^a   Way, S L ^a   Granter, N ^a   Spencer, A ^a  

^a NEWCASTLE MATER HOSPITAL   (Australia)

Author keywords

ASO PCR; Autologous stem cell transplantation; Bone marrow; Multiple myeloma; Peripheral blood

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; OLIGONUCLEOTIDE; PARAPROTEIN;

ADULT; ALLELE; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD; BONE MARROW; CELL COUNT; CELL KINETICS; CELL MOTILITY; CELL TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HUMAN; HUMAN CELL; LEUKAPHERESIS; MALE; MORPHOLOGY; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STEM CELL; THEORY; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH;

EID: 0035034489     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109057937     Document Type: Article

References (44)

1. Criteria for evaluating disease response and progression in multiple myeloma patients treated by high dose therapy and haemopoietic stem cell transplantation
2. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma
3. Multiple myeloma: Increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival
4. Clonal circulating cells are common in plasma cell proliferative disorders: A comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma
5. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma
6. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants
7. Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma
8. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests
9. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts
10. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients
11. Molecular detection of tumor contamination in peripheral blood stem cell harvests
12. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy
13. High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting
14. Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: When is the optimal time for stem cell harvest?
15. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
16. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML
17. Monoclonal plasma cells in the blood stem cell harvests from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation
18. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumours
19. A phase II study of CID therapy and early PBSCT in patients with de novo multiple myeloma
20. A simple salting out procedure for extracting DNA from human nucleated cells
21. Clonal instability preceeding lymphoid blastic transformation of chronic myeloid leukemia
22. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies
23. Immunoglobulin gene "fingerprinting": An approach to analysis of B lymphoid clonality in lymphoproliferative disorders
24. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops
25. Independent origin of single and double mutations in the human glucose 6-phosphate dehydrogenase gene
26. VH gene usage in multiple myeloma: Complete absence of the VH4.21 (VH4-34) gene
27. Assessment of IgH PCR strategies in multiple myeloma
28. Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-lymphocyte clones in a polyclonal population
29. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: A technique for sequential quantitation of residual disease
30. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor
31. A rationale for positive selection of peripheral blood stem cells in multiple myeloma: Highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cells
32. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards
33. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients
34. Detection of circulating tumor cells in multiple myeloma by a PCR-based method
35. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain
36. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase- reaction
37. Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumour involvement
38. First and second apheresis in patients with multiple myeloma: No differences in tumour load and hematopoietic stem cell yeild
39. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma
40. Purified CD34+ Lin-Thy+ stem cells do not contain clonal myeloma cells
41. Multiple myeloma: Reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses
42. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
43. Response patterns of purified myeloma cells to hematopoietic growth factors
44. Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity